X

Trial Profile

The clinical research of Mesylate apatinib combined with docetaxel and S-1 as the first-line treatment of metastatic gastric cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 May 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

Most Recent Events

08 Jun 2021 Results (n=44) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
08 Dec 2020 Planned End Date changed from 20 Nov 2019 to 31 Dec 2021.
08 Dec 2020 Planned primary completion date changed from 20 Feb 2018 to 31 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com